Dorato Capital Management Takes Position in Merck & Co., Inc. $MRK

Dorato Capital Management acquired a new position in Merck & Co., Inc. (NYSE:MRK) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 16,300 shares of the company’s stock, valued at approximately $1,809,000. Merck & Co., Inc. accounts for 1.4% of Dorato Capital Management’s investment portfolio, making the stock its 15th largest position.

Several other large investors also recently added to or reduced their stakes in the company. Darwin Wealth Management LLC boosted its position in shares of Merck & Co., Inc. by 237.4% in the third quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock worth $26,000 after buying an additional 216 shares during the period. Kilter Group LLC acquired a new position in Merck & Co., Inc. during the second quarter valued at $27,000. Barnes Dennig Private Wealth Management LLC lifted its stake in Merck & Co., Inc. by 302.3% in the 3rd quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock worth $30,000 after acquiring an additional 266 shares in the last quarter. Evolution Wealth Management Inc. purchased a new stake in Merck & Co., Inc. in the 2nd quarter worth about $31,000. Finally, United Financial Planning Group LLC acquired a new stake in Merck & Co., Inc. during the 3rd quarter worth about $31,000. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Performance

Shares of MRK opened at $120.62 on Friday. The firm has a market cap of $298.21 billion, a price-to-earnings ratio of 16.57, a price-to-earnings-growth ratio of 2.44 and a beta of 0.26. The company’s fifty day moving average is $117.47 and its 200-day moving average is $102.80. The company has a quick ratio of 1.30, a current ratio of 1.54 and a debt-to-equity ratio of 0.89. Merck & Co., Inc. has a 12 month low of $73.31 and a 12 month high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.01 by $0.03. The business had revenue of $16.40 billion during the quarter, compared to analyst estimates of $16.19 billion. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. Merck & Co., Inc.’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.72 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Equities analysts expect that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th will be given a $0.85 dividend. The ex-dividend date of this dividend is Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.8%. Merck & Co., Inc.’s payout ratio is currently 46.70%.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: European approval expands KEYTRUDA use to a platinum‑resistant ovarian cancer population (PD‑L1 CPS ≥1). This label adds a new, high‑need indication and could incrementally lift oncology sales in Europe if uptake is steady; approval reduces regulatory uncertainty for the combo in that market. Merck granted EU approval of Keytruda combo in ovarian cancer
• Positive Sentiment: European Commission press release confirming KEYTRUDA + paclitaxel ± bevacizumab approval for PD‑L1‑positive, platinum‑resistant recurrent ovarian carcinoma — reinforces the commercial significance of the approval and the company’s oncology momentum in EU markets. European Commission Approves KEYTRUDA combo
• Positive Sentiment: Merck reported strong Phase 3 results for an oral PCSK9 candidate (enlicitide decanoate) — if confirmed through regulatory paths, an oral PCSK9 could be a major commercial opportunity in lipid management and compete with injectables, implying material long‑term upside to cardiovascular franchise revenue. Merck Reports Strong Phase 3 Results for Oral PCSK9
• Positive Sentiment: Initiation of a pivotal Phase 2b/3 trial for MK‑8748 (Tiespectus) in neovascular AMD shows Merck advancing a novel bispecific Tie2 agonist/VEGF inhibitor into registrational testing — de‑risks a promising ophthalmology program and could add a new specialty product if successful. Merck Announces Initiation of Pivotal Phase 2b/3 Trial
• Positive Sentiment: Royal Bank of Canada assigned an Outperform rating — analyst upgrades/support can buoy sentiment and buying interest, especially when coupled with pipeline news and recent beats. Merck Earns Outperform Rating from RBC
• Neutral Sentiment: Merck released detailed Phase 2 CADENCE data (WINREVAIR) — more granular data helps investors assess clinical profile and commercial potential, but Phase 2 detail typically moves shares less than registrational results unless outcomes are transformational. Merck Announces Detailed Results From the Phase 2 CADENCE Study
• Neutral Sentiment: Merck completed the acquisition of JSR Life Sciences’ chromatography business — broadens manufacturing/service capabilities (note: some headlines refer to Merck KGaA; confirm scope). Strategic but not immediately revenue‑moving for MRK’s core drug sales. Merck Completes Acquisition of JSR Life Sciences’ Chromatography Business
• Neutral Sentiment: Sector commentary: Lilly warned against locking pricing‑deal rules into law, citing innovation risk — a reminder of policy/regulatory uncertainty that can affect the whole pharma sector, including MRK, but it’s not a company‑specific development. Lilly Pushes Back on Making Drug Price Deals Permanent

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Zacks Research raised Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 17th. Weiss Ratings restated a “hold (c)” rating on shares of Merck & Co., Inc. in a report on Monday, December 29th. Barclays assumed coverage on shares of Merck & Co., Inc. in a research report on Friday, February 20th. They set an “overweight” rating and a $140.00 price objective on the stock. Wolfe Research upgraded shares of Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 target price for the company in a research report on Thursday, January 8th. Finally, TD Cowen lifted their target price on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the company a “hold” rating in a research note on Tuesday, January 20th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and a consensus price target of $127.13.

Insider Activity at Merck & Co., Inc.

In related news, EVP David Michael Williams sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $121.91, for a total value of $609,550.00. Following the completion of the sale, the executive vice president directly owned 30,838 shares in the company, valued at approximately $3,759,460.58. The trade was a 13.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Johannes Jacobus Oosthuizen sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $121.87, for a total value of $1,828,050.00. Following the sale, the insider directly owned 21,197 shares of the company’s stock, valued at $2,583,278.39. The trade was a 41.44% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 320,176 shares of company stock worth $38,281,735 in the last 90 days. Insiders own 0.13% of the company’s stock.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.